Rigel Submits New Drug Application to FDA for Fostamatinib in Chronic ITP

SOUTH SAN FRANCISCO, Calif., April 17, 2017 -- (Healthcare Sales & Marketing Network) -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for fosta... Biopharmaceuticals Rigel Pharmaceuticals, fostamatinib, immune thrombocytopenia

http://salesandmarketingnetwork.com/news_release_bs.html?ID=2042399

Source: HSMN NewsFeed - April 17, 2017 Category: Pharmaceuticals Source Type: news

More News: Food and Drug Administration (FDA) | Marketing | New Drug Applications | Pharmaceuticals | Thrombocytopenia